These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33233768)

  • 1. IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies.
    Kirchhoff D; Stelte-Ludwig B; Lerchen HG; Wengner AM; Ahsen OV; Buchmann P; Märsch S; Mahlert C; Greven S; Dietz L; Erkelenz M; Zierz R; Johanssen S; Mumberg D; Sommer A
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
    Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
    Kovtun Y; Jones GE; Adams S; Harvey L; Audette CA; Wilhelm A; Bai C; Rui L; Laleau R; Liu F; Ab O; Setiady Y; Yoder NC; Goldmacher VS; Chari RVJ; Pinkas J; Chittenden T
    Blood Adv; 2018 Apr; 2(8):848-858. PubMed ID: 29661755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
    Willuda J; Linden L; Lerchen HG; Kopitz C; Stelte-Ludwig B; Pena C; Lange C; Golfier S; Kneip C; Carrigan PE; Mclean K; Schuhmacher J; von Ahsen O; Müller J; Dittmer F; Beier R; El Sheikh S; Tebbe J; Leder G; Apeler H; Jautelat R; Ziegelbauer K; Kreft B
    Mol Cancer Ther; 2017 May; 16(5):893-904. PubMed ID: 28292941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.
    Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR
    Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
    Li F; Sutherland MK; Yu C; Walter RB; Westendorf L; Valliere-Douglass J; Pan L; Cronkite A; Sussman D; Klussman K; Ulrich M; Anderson ME; Stone IJ; Zeng W; Jonas M; Lewis TS; Goswami M; Wang SA; Senter PD; Law CL; Feldman EJ; Benjamin DR
    Mol Cancer Ther; 2018 Feb; 17(2):554-564. PubMed ID: 29142066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.
    Agger K; Miyagi S; Pedersen MT; Kooistra SM; Johansen JV; Helin K
    Genes Dev; 2016 Jun; 30(11):1278-88. PubMed ID: 27257215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.
    Hou Z; Ren Y; Zhang X; Huang D; Yan F; Sun W; Zhang W; Zhang Q; Fu X; Lang Z; Chu C; Zou B; Gao B; Jin B; Kang Z; Liu Q; Yan J
    Cell Commun Signal; 2024 Apr; 22(1):211. PubMed ID: 38566191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
    Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
    Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
    Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
    Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
    [No Abstract]   [Full Text] [Related]  

  • 12. IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
    Cardillo TM; Govindan SV; Zalath MB; Rossi DL; Wang Y; Chang CH; Goldenberg DM
    Mol Cancer Ther; 2018 Jan; 17(1):150-160. PubMed ID: 29133623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.
    Abrams T; Connor A; Fanton C; Cohen SB; Huber T; Miller K; Hong EE; Niu X; Kline J; Ison-Dugenny M; Harris S; Walker D; Krauser K; Galimi F; Wang Z; Ghoddusi M; Mansfield K; Lee-Hoeflich ST; Holash J; Pryer N; Kluwe W; Ettenberg SA; Sellers WR; Lees E; Kwon P; Abraham JA; Schleyer SC
    Clin Cancer Res; 2018 Sep; 24(17):4297-4308. PubMed ID: 29764854
    [No Abstract]   [Full Text] [Related]  

  • 14. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
    Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
    Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia.
    Barwe SP; Kisielewski A; Bonvini E; Muth J; Davidson-Moncada J; Kolb EA; Gopalakrishnapillai A
    J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
    Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
    Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
    Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
    Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
    Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
    Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.
    Cheng Y; Yuan X; Tian Q; Huang X; Chen Y; Pu Y; Long H; Xu M; Ji Y; Xie J; Tan Y; Zhao X; Song H
    Front Oncol; 2022; 12():951589. PubMed ID: 36620535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
    Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
    Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.